{"title":"体内观察经脓疱疮抗原处理的中性粒细胞对从血管脓疱病患者体内分离出的三种脓疱疮菌株的影响。","authors":"Sadeep Medhasi, Apichaya Sriwarom, Nitipong Permpalung, Pattama Torvorapanit, Rongpong Plongla, Ariya Chindamporn, Navaporn Worasilchai","doi":"10.1080/21645515.2024.2304372","DOIUrl":null,"url":null,"abstract":"<p><p>The mechanisms of <i>Pythium insidiosum</i>-antigen (PIA) immunotherapy activating a patient's immune system are unknown. We evaluated the interleukin-8 (IL-8) serum levels during <i>P. insidiosum</i> infection and after vaccination with PIA in vascular pythiosis cases. Furthermore, we studied the anti-<i>P. insidiosum</i> activity of neutrophils stimulated with various concentrations of PIA <i>ex vivo</i> in 3 strains of <i>P. insidiosum</i> isolated from vascular pythiosis patients. IL-8 serum levels were evaluated using the ELISA technique. We assessed the effect of PIA-stimulated neutrophils on the viability of zoospores using MTT assay, visualized neutrophil extracellular trap (NET) formation via microscopy, and measured the levels of double-stranded DNA (dsDNA) using PicoGreen dsDNA quantitation assay in 3 strains of <i>P. insidiosum</i> isolated from vascular pythiosis patients. Serum levels of IL-8 gradually lowered from the early to the end phases of vaccination with PIA among the surviving group of vascular pythiosis cases. Neutrophils stimulated with 0.01 µg/ml PIA reduced zoospore viability significantly compared to PIA-unstimulated neutrophils for strain 1 and strain 3 (<i>p</i> < .05). Neutrophils stimulated with 0.01, 0.1, 1, and 10 µg/ml PIA exhibited significantly lower zoospore viability than PIA-unstimulated neutrophils for strain 2 (<i>p</i> < .05). IL-8 can be used as a biomarker for monitoring vascular pythiosis cases treated with the PIA vaccine. Also, anti-<i>P. insidiosum</i> activity of PIA-stimulated neutrophils was probably due to the disruption of cellular activity in zoospores rather than the mechanisms based on the formation of NETs.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10854268/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>Ex vivo</i> observation of <i>Pythium insidiosum</i>-antigen treated neutrophils on three <i>Pythium insidiosum</i> strains isolated from vascular pythiosis patients.\",\"authors\":\"Sadeep Medhasi, Apichaya Sriwarom, Nitipong Permpalung, Pattama Torvorapanit, Rongpong Plongla, Ariya Chindamporn, Navaporn Worasilchai\",\"doi\":\"10.1080/21645515.2024.2304372\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The mechanisms of <i>Pythium insidiosum</i>-antigen (PIA) immunotherapy activating a patient's immune system are unknown. We evaluated the interleukin-8 (IL-8) serum levels during <i>P. insidiosum</i> infection and after vaccination with PIA in vascular pythiosis cases. Furthermore, we studied the anti-<i>P. insidiosum</i> activity of neutrophils stimulated with various concentrations of PIA <i>ex vivo</i> in 3 strains of <i>P. insidiosum</i> isolated from vascular pythiosis patients. IL-8 serum levels were evaluated using the ELISA technique. We assessed the effect of PIA-stimulated neutrophils on the viability of zoospores using MTT assay, visualized neutrophil extracellular trap (NET) formation via microscopy, and measured the levels of double-stranded DNA (dsDNA) using PicoGreen dsDNA quantitation assay in 3 strains of <i>P. insidiosum</i> isolated from vascular pythiosis patients. Serum levels of IL-8 gradually lowered from the early to the end phases of vaccination with PIA among the surviving group of vascular pythiosis cases. Neutrophils stimulated with 0.01 µg/ml PIA reduced zoospore viability significantly compared to PIA-unstimulated neutrophils for strain 1 and strain 3 (<i>p</i> < .05). Neutrophils stimulated with 0.01, 0.1, 1, and 10 µg/ml PIA exhibited significantly lower zoospore viability than PIA-unstimulated neutrophils for strain 2 (<i>p</i> < .05). IL-8 can be used as a biomarker for monitoring vascular pythiosis cases treated with the PIA vaccine. Also, anti-<i>P. insidiosum</i> activity of PIA-stimulated neutrophils was probably due to the disruption of cellular activity in zoospores rather than the mechanisms based on the formation of NETs.</p>\",\"PeriodicalId\":49067,\"journal\":{\"name\":\"Human Vaccines & Immunotherapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10854268/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Vaccines & Immunotherapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21645515.2024.2304372\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2304372","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
脓疱疮抗原(PIA)免疫疗法激活患者免疫系统的机制尚不清楚。我们评估了血管脓疱病病例在感染脓疱疮期间和接种脓疱疮疫苗后的白细胞介素-8(IL-8)血清水平。此外,我们还研究了从血管脓毒血症患者体内分离出的 3 株 P. insidiosum,用不同浓度的 PIA 在体外刺激中性粒细胞的抗 P. insidiosum 活性。使用 ELISA 技术评估了 IL-8 血清水平。我们使用 MTT 试验评估了 PIA 刺激的中性粒细胞对动物孢子活力的影响,通过显微镜观察了中性粒细胞胞外捕获器(NET)的形成,并使用 PicoGreen dsDNA 定量分析法测定了从血管脓疱病患者体内分离出的 3 株 P. insidiosum 的双链 DNA(dsDNA)水平。在血管性脓疱病存活病例组中,IL-8的血清水平从接种PIA初期到末期逐渐降低。与未受 PIA 刺激的中性粒细胞相比,受 0.01 µg/ml PIA 刺激的中性粒细胞可显著降低 1 号菌株和 3 号菌株的虫孢子活力(p p P. insidiosum),PIA 刺激的中性粒细胞的活性可能是由于破坏了虫孢子的细胞活性,而不是基于 NET 的形成机制。
Ex vivo observation of Pythium insidiosum-antigen treated neutrophils on three Pythium insidiosum strains isolated from vascular pythiosis patients.
The mechanisms of Pythium insidiosum-antigen (PIA) immunotherapy activating a patient's immune system are unknown. We evaluated the interleukin-8 (IL-8) serum levels during P. insidiosum infection and after vaccination with PIA in vascular pythiosis cases. Furthermore, we studied the anti-P. insidiosum activity of neutrophils stimulated with various concentrations of PIA ex vivo in 3 strains of P. insidiosum isolated from vascular pythiosis patients. IL-8 serum levels were evaluated using the ELISA technique. We assessed the effect of PIA-stimulated neutrophils on the viability of zoospores using MTT assay, visualized neutrophil extracellular trap (NET) formation via microscopy, and measured the levels of double-stranded DNA (dsDNA) using PicoGreen dsDNA quantitation assay in 3 strains of P. insidiosum isolated from vascular pythiosis patients. Serum levels of IL-8 gradually lowered from the early to the end phases of vaccination with PIA among the surviving group of vascular pythiosis cases. Neutrophils stimulated with 0.01 µg/ml PIA reduced zoospore viability significantly compared to PIA-unstimulated neutrophils for strain 1 and strain 3 (p < .05). Neutrophils stimulated with 0.01, 0.1, 1, and 10 µg/ml PIA exhibited significantly lower zoospore viability than PIA-unstimulated neutrophils for strain 2 (p < .05). IL-8 can be used as a biomarker for monitoring vascular pythiosis cases treated with the PIA vaccine. Also, anti-P. insidiosum activity of PIA-stimulated neutrophils was probably due to the disruption of cellular activity in zoospores rather than the mechanisms based on the formation of NETs.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.